March 22 (Reuters) - Abbvie Inc:
* ABBVIE ANNOUNCES RESULTS FROM PHASE 2 STUDY EVALUATING ROVALPITUZUMAB TESIRINE (ROVA-T) FOR THIRD-LINE TREATMENT OF PATIENTS WITH DLL3-EXPRESSING RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
* ABBVIE INC - WILL NOT SEEK ACCELERATED APPROVAL FOR ROVA-T IN THIRD-LINE RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
* ABBVIE INC - SAFETY DATA IN TRINITY STUDY WERE CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF ROVA-T
* ABBVIE INC - ROVA-T DEMONSTRATED SINGLE AGENT RESPONSES IN ADVANCED SCLC PATIENTS
* ABBVIE INC - ONGOING PHASE 3 STUDIES, MERU AND TAHOE, WILL CONTINUE TO INVESTIGATE ROVA-T IN FIRST- AND SECOND-LINE SCLC Source text for Eikon: Further company coverage:
